Ghent, Belgium – 6 June 2013 – The United States Patent and Trade Office (USPTO) has allowed Pronota’s patent for the use of a blood-based biomarker LG3 in the decision-making process for the treatment of renal dysfunction. This is a major step forward for Pronota as it reconfirms the patentability of the use of biomarkers. More… »
Leiden, the Netherlands—May 28, 2013 — Prosensa Holding B.V., today announced that it has filed a registration statement on Friday May 24, 2013 on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the offering have not been determined.
J.P. Morgan and Citigroup are acting as joint book-running managers for the offering. Leerink Swann is acting as lead manager and Wedbush PacGrow Life Sciences and KBC Securities are acting as co-managers. More… »
Ghent, Belgium, 18 april 2013 – Two independent validation studies demonstrate that Pronota’s biomarker CD146 significantly improves the diagnosis of acute heart failure for patients with shortness of breath. The biomarker, measured in blood, provides clinicians with unique additional information allowing better treatment of this challenging group of patients. More… »
Groningen, The Netherlands, 15 maart 2013 - Groningen to be the first to keep a liver warm outside a human body. Researchers and liver surgeons at the University Medical Center in Groningen in the Netherlands have been the first to successfully keep a liver at body temperature outside a human body. With this technique, a donor liver can be tested before being transplanted. More… »
Leiden, The Netherlands – 27 February 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, received the ‘Company Award’ at the EURORDIS Black Pearl Gala Dinner in Brussels last night. More… »